PT - JOURNAL ARTICLE AU - Stoddard, Madison AU - Yuan, Lin AU - Sarkar, Sharanya AU - Mangalaganesh, Shruthi AU - Nolan, Ryan P. AU - Bottino, Dean AU - Hather, Greg AU - Hochberg, Natasha S. AU - White, Laura F. AU - Chakravarty, Arijit TI - Heterogeneity in vaccinal immunity to SARS-CoV-2 can be addressed by a personalized booster strategy AID - 10.1101/2022.08.30.22279397 DP - 2022 Jan 01 TA - medRxiv PG - 2022.08.30.22279397 4099 - http://medrxiv.org/content/early/2022/09/01/2022.08.30.22279397.short 4100 - http://medrxiv.org/content/early/2022/09/01/2022.08.30.22279397.full AB - The ongoing COVID-19 pandemic has placed an unprecedented burden on global health. Crucial for managing this burden, the existing SARS-CoV-2 vaccines have substantially reduced the risk of severe disease and death up to this point. The induction of neutralizing antibodies (nAbs) by these vaccines leads to protection against both infection and severe disease. However, pharmacokinetic (PK) waning and rapid viral evolution degrade neutralizing antibody binding titers, leading to a rapid loss of vaccinal protection against infection occurring on the order of months after vaccination. Additionally, inter-individual heterogeneity in the strength and durability of the vaccine-induced neutralizing response to SARS-CoV-2 can create a further public-health risk by placing a subset of the population at risk. Here we incorporate the heterogeneity in inter-individual response into a pharmacokinetic/ pharmacodynamic (PK/PD) model to project the degree of heterogeneity in immune protection. We extend our model-based approach to examine the impact of evolutionary immune evasion on vaccinal protection. Our findings suggest that viral evolution can be expected to impact the effectiveness of vaccinal protection against severe disease, particularly for individuals with a shorter duration of immune response. One possible solution to immune heterogeneity may be more frequent boosting for individuals with a weaker immune response. We demonstrate a model-based approach to targeted boosting that involves the use of the ECLIA RBD assay to identify individuals whose immune response is insufficient for protection against severe disease. Our work suggests that vaccinal protection against severe disease is not assured and provides a path forward to reducing the risk to immunologically vulnerable individuals.Competing Interest StatementMS, LY, and AC are employees of Fractal Therapeutics, Inc.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used clinical antibody PK data published by Moderna in the following study: Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination https://www.nejm.org/doi/full/10.1056/NEJMc2032195I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.